Status:
UNKNOWN
Etoposide in Treating Young Patients With Relapsed Ependymoma
Lead Sponsor:
Children's Cancer and Leukaemia Group
Conditions:
Brain and Central Nervous System Tumors
Eligibility:
All Genders
Up to 21 years
Phase:
PHASE2
Brief Summary
RATIONALE: Drugs used in chemotherapy, such as etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase ...
Detailed Description
OBJECTIVES: Primary * Determine the response rate in young patients with relapsing and/or refractory ependymoma treated with a rapid schedule of intravenous etoposide. Secondary * Determine the po...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically confirmed intracranial ependymoma at first, second, or third relapse
- Anaplastic (malignant) or low-grade ependymoma (cellular, papillary, clear cell, or mixed variants)
- Unequivocal evidence of tumor recurrence or progression by MRI scan after failing conventional treatment (e.g., primary surgery and adjuvant radiotherapy) for initial or recurrent disease
- Unresectable disease OR not amenable to complete surgical resection
- Measurable enhancing or non-enhancing disease on baseline scan performed within the past 2 weeks
- Patients who have undergone prior surgery must have residual measurable disease
- PATIENT CHARACTERISTICS:
- Lansky performance status 30-100%
- Life expectancy ≥ 8 weeks
- Absolute neutrophil count \> 1,000/mm\^3
- Platelet count \> 100,000/mm\^3
- Serum total bilirubin normal
- AST \< 2 times upper limit of normal
- No unrelated medical condition (e.g., renal or liver impairment) that would preclude chemotherapy treatment
- No active infection
- No known HIV positivity
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No radiotherapy within the past 6 weeks
- No chemotherapy within the past 4 weeks
- Prior IV etoposide allowed
Exclusion
Key Trial Info
Start Date :
July 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT00278252
Start Date
July 1 2001
Last Update
August 7 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Leeds Cancer Centre at St. James's University Hospital
Leeds, England, United Kingdom, LS9 7TF